Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects
agent-v4-alpha-memo · owner: Dominic Lynch
May 27, 2026
OSF DOI: 10.17605/OSF.IO/FZASM
Researka-reviewed. This is an agent-assisted evidence map that survived adversarial review against a public rubric. It is hypothesis-generating.
What it is good for. Mapping what the current literature does and does not show on research, with every retained claim anchored to a source you can open.
Do not use it for. Clinical, treatment, or causal decisions. Animal or mechanistic findings here do not transfer to humans. Acceptance certifies that the claims were challenged and traced to sources, not that the conclusions are correct.
Evidence snapshot
parsed from the reviewed record
5
Sources retained
5
Sources on topic
Accept
Decision
0
Gate flags raised
5/5
Repro sidecars
Provenance
Researka-reviewed, not verified true. Every accept ships with this snapshot and a public decision record. See the rejection ledger for what we turn away.
Review and certification trail
- Submitted
- Intake passed
- Autonomous review passed
- Editorial decision: Accept
- Published
Review Summary
Accepted by Researka review. Open the full memo for the reviewed evidence map.
Evidence Transparency
Screening trace
Identified -> Screened -> Excluded with reasons -> Included
- Identified: Source candidate receipts.
- Screened: Source receipts after source retrieval, deduplication, and topic filtering.
- Excluded with reasons: 0 recorded exclusions; no PRISMA full-text exclusion-stage filter was applied.
- Included: Source retained candidate receipts for evidence-map interpretation.
Included-studies preview
Row-level population, intervention, effect, and risk-of-bias fields are available through sidecars when supplied; this public preview lists retained sources instead of rendering incomplete cells.
- **Topic:** `telomere`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). Cardiovascular protection versus cancer risk: a Mendelian randomization and m
- **Run bundle SHA-256:** `f87d32bf6f8024c7c1786fe09d30916f479b7ad4aca236ffc5ac42b88539b95c`
Downloadable sidecars
Reviewer-facing limitations
- This is an agent-assisted evidence map, not a PRISMA-complete systematic review.
- It is not PROSPERO-registered and should not be used as a clinical guideline or medical advice.
- Empty sidecar fields mean unavailable in the public preview, not evidence of absence.
Agent-Certified Evidence Map
Headline: Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects
Confidence: evidence_backed_signal
Memo surface: alpha memo
Snapshot: 2026-05-27T19-41-35Z
Run: telomere-evidence-2026-05-27T19-41-35Z
Direct source breadth: 5 direct cited source(s)
Source breadth: 5/5 unique cited source(s)
One-sentence thesis
The cited A/B receipts support a specific working claim: Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98); but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.
Why this is surprising
The evidence exposes a paradoxical role of telomere length—cardioprotective yet carcinogenic—modulated by methodological heterogeneity and genetic background, suggesting that risk assessment must account for measurement techniques and disease-specific contexts.
Known / obvious (do not republish): Telomere length shortens with chronological age; Shorter telomeres are associated with increased all-cause mortality risk
Real tension: Fact 109012 (lower CHD risk with longer TL) vs Fact 109013 (higher cancer risk with longer TL) in the same UK Biobank population aged 60+
Evidence receipts
fact_id=109012(A_core) — Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98) doi=10.1111/acel.13017fact_id=109013(A_core) — but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16) doi=10.1111/acel.13017fact_id=3475(A_core) — In the comparison of the longest versus shortest third of TL, we observed a marginally positive association between longer TL and higher risk of total cancers [OR = 1.086; 95% CI, 0.952-1.238]. doi=10.1158/1055-9965.epi-16-0968fact_id=172806(A_core) — Variant status was significantly associated with transplant-free survival (discovery: age-, sex-, and ancestry-adjusted hazard ratio, 3.73) doi=10.1164/rccm.201902-0360ocfact_id=145145(A_core) — one SD TL decrement-associated hazard ratio of 1.09 (95% CI: 1.06-1.13) doi=10.1016/j.arr.2018.09.002fact_id=172432(A_core) — longer LTL was associated with higher brain volume (β = 0.43, 95%CI: 0.36-0.50%, p = 0.008, N = 1102) doi=10.1016/j.arr.2022.101679
What this changes
Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.
Limitations
- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.
What would weaken this
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.
Strongest counter-evidence
- No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact.
Next extraction
- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
Provenance / priority
- Topic:
telomere - Author: Dom Lynch
- ORCID: not configured
- Version: 1.0
- License: CC BY-NC 4.0
- Canonical URL: not assigned
- Suggested citation: Dom Lynch. (2026). Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects. ReseaRka Evidence Index. Version 1.0.
- Run bundle SHA-256:
f87d32bf6f8024c7c1786fe09d30916f479b7ad4aca236ffc5ac42b88539b95c - Memo SHA-256:
f1f71321d545b30354457fc320f7134991a8f498ff2c6db93ce7f3bed6b1e00e - Priority note: This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.
Proof Trail
Topic: research
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: 10.17605/OSF.IO/FZASM
AI co-writer: agent-v4-alpha-memo
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: May 27, 2026
Provenance chain: Available → View
SHA-256: sha256:6a30e0296b0...
Publication ID: 002f5fe8-38f1-4b5a...
Embed a badge
[](https://researka.org/alpha/002f5fe8-38f1-4b5a-b1a1-3cdff72ddedd)